TROY LUNCEFORD: Open Payments
NPI 1194842286 · SALEM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,295 in 198 payments from 20 companies in 2025. Trend: 2023 $1,664 · 2024 $2,525 · 2025 $2,295
Food & beverage: $2,295
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $388 |
| Astellas Pharma US Inc | 11 | $219 |
| PFIZER INC. | 21 | $203 |
| AstraZeneca Pharmaceuticals LP | 8 | $201 |
| Novo Nordisk Inc | 26 | $198 |
| Axsome Therapeutics, Inc. | 10 | $192 |
| Amgen Inc. | 15 | $169 |
| Otsuka America Pharmaceutical, Inc. | 12 | $169 |
| Aimmune Therapeutics, Inc. | 15 | $142 |
| Lilly USA, LLC | 27 | $113 |
Products named: Veozah, VRAYLAR, REXULTI, FARXIGA, ZENPEP, QULIPTA, NURTEC ODT, MOUNJARO.
Industry payments across UT — which companies pay providers there.
